Mankind Pharma stock
MANKIND.NSNSEMankind Pharma Limited, HealthcareISIN INE634S01028
65Score 65 out of 100, Neutral
Price and trend
74 / 100
Price history
+16% in one yearThe chart shows daily closes over 4 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 13% above it.
Since June 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Overheated: the price has risen very quickly lately (RSI 84).
The price is 1.1% below its 52-week high. Largest decline in 4 years: 36% (December 2024 to March 2026).
Chart figures for advanced users
- SMA 50$25.66
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$24.77
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)84
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$20.49
- The lowest closing price of the last twelve months.
- Resistance$28.36
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Mankind Pharma Limited belongs to the Drug Manufacturers (Specialty & Generic) industry (India) and, with a market value of $11.58B, is number 25 of 77 companies in its industry on MEQIRI.
- In fiscal 2026 it reported revenue of $1.52B (up 17% year on year) and earnings of $203.32M (down 3.9%).
- For fiscal 2027, analysts expect on average revenue of $1.73B (up 14.2%) and adjusted earnings per share of $0.63 (up 19.6%).
Show more
- MEQIRI Score 65 out of 100 (Neutral): rank 212 of 702 in Healthcare, median 53.
- The P/E is 48.7 (Drug Manufacturers (Specialty & Generic) median 32.5, own median of recent years 48.4).
- Our model puts fair value at $18.84, with the price 49% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 18.1% a year since 2021, Drug Manufacturers (Specialty & Generic) median 10.2%.Growth 61
- Consistently profitableProfit in all 8 fiscal years from 2019 to 2026.Fundamentals 67
- Analysts expect strong earnings growthUp 19.9% a year through 2029 (estimates from 17 analysts).Growth 61
Weaknesses
- Above fair valuePrice 49% above the fair value of $18.84.Valuation 26
Its standout strengths are technical analysis and momentum, while valuation holds the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk not measured
How well MEQIRI warnsFor stocks from Japan, China, Hong Kong, Taiwan, Korea, Canada, India and Brazil we only show crash risk once a separate backtest shows that it warns as well there as in the US and Europe.
Valuation
Valuation signal
Significantly overvaluedIn our model the price counts as cheap below $14.49 and expensive above $26.91 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $18.92 (cash-flow model) and $18.75 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is above both.
Calculated with a cost of equity of 12.6%. At 13.6% the fair value would be $17.31, at 11.6% it would be $21.02.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (32.5).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 14.1% on the twelve months before. Revenue has grown strongly since 2019, at around 16% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2026: gross 43%, operating 19%, net 13%.
Debt & balance sheet
latest quarterModerate debt, and interest is adequately covered.
Earnings
- Next earnings
- 3 Feb 2027in 82 days
- Last reported
- 26 Oct 2026EPS reported $0.18 (expected $0.16)above expectations
Analyst estimates
Analysts have raised their 2027 earnings estimate by 3.1% since 26 Oct 2026.
- Earnings per share
- $0.63+3.1%
- Revenue
- $1.73B+1.4%
- Earnings per share
- $0.77+2.7%
- Revenue
- $1.94B+1.8%
MEQIRI has stored the estimates since 26 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook mixed
Share price after the results: +13.1%Mankind confirms its FY2027 margin guidance of 25.5% to 26.5% but lowers the consumer business growth outlook to single digit from high single digit to low double digit, while export growth and operating margin are running above prior guidance.
“As far as the margin guidance is concerned, we would like to maintain the same guidance, 25.5%-26.5%.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 26 Oct 2026 (fiscal Q2 2027), read by AI.
What happened at Mankind Pharma
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 65
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Drug Manufacturers (Specialty & Generic)
The next larger and next smaller companies by market value
- Zydus LifesciencesZYDUSLIFE.NS $12.79B69
- Dr. Reddy's LaboratoriesRDY $12.28B62
- CiplaCIPLA.NS $12.09B67
- Zhejiang NHU002001.SZ $11.75B75
- Aurobindo PharmaAUROPHARMA.NS $11.05B67
- LupinLUPIN.NS $9.79B76
- Eisai4523.T $9.14B62
- Shanghai Fosun Pharmaceutical (Group)600196.SS $9.13B47
ETFs that hold Mankind Pharma
Held by 16 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares MSCI India UCITS ETFQDV5 | 0.19% | 0.65% | €4.98B |
| iShares MSCI EM Consumer Growth UCITS ETFCEMG | 0.12% | 0.60% | €31.52M |
| Amundi MSCI EM Asia ESG Broad Transition UCITS ETF AccLCUA | 0.08% | 0.25% | €661.06M |
Show 5 more
| iShares MSCI EM CTB Enhanced ESG UCITS ETFEDM2 | 0.07% | 0.18% | €7.25B |
| WisdomTree Emerging Markets ex-State Owned Enterprises UCITS ETF AccumUSDXSOE | 0.05% | 0.32% | €17.98M |
| iShares MSCI EM Asia UCITS ETFCEBL | 0.03% | 0.20% | €7.14B |
| iShares Core MSCI EM IMI UCITS ETFIS3N | 0.03% | 0.18% | €37.98B |
| Amundi Core MSCI Emerging Markets UCITS ETF EUR DistAEMD | 0.03% | 0.18% | €9.52B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 31 Mar 2026
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = ₹94.0836)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 26 Sep 2025)
- Valuation signal Overvalued since 9 Nov 2026, previously Fairly valued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.